Mehrdad Hashemi | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Prof. Mehrdad Hashemi | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Tehran Medical Sciences, Islamic Azad University | Iran

Professor Mehrdad Hashemi is a renowned scholar in Molecular and Medical Genetics whose pioneering research has made transformative contributions to predictive, preventive, and personalized medicine. His scientific work focuses on the discovery of diagnostic and therapeutic biomarkers particularly non-coding RNAs (lncRNAs and miRNAs) with profound implications for early disease detection, molecular targeting, and precision therapy. Prof. Mehrdad Hashemi has authored 372 peer-reviewed publications indexed in Scopus, accumulating over 6,826 citations from 6,242 documents, and achieving a remarkable h-index of 41. His research portfolio includes 299 ISI-indexed papers, 342 Scopus-indexed papers, and 258 PubMed articles, encompassing 119 Q1 and 82 Q2 journals. He has led or completed 14 major research projects, contributed to 95 industrial and academic collaborations, and maintained 110 international research partnerships with leading institutions across the USA, UK, Canada, China, Germany, Australia, and beyond. His scholarly output also includes 3 internationally published books and 1 patent. Ranked among the World’s Top 1% and 2% Scientists in both ESI (2024) and Stanford (2024–2025) global rankings, Prof. Mehrdad Hashemi’s groundbreaking studies on exosomes, nanomedicine, gene regulation, and cancer therapeutics have advanced global understanding of disease mechanisms and innovative treatment modalities. He also contributes extensively as an editorial board member, peer reviewer, and thought leader in the field of molecular diagnostics and translational genetics.

Profiles: Scopus | Google Scholar | ORCID | Staff Page

Featured Publications

  • Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., … & Hashemi, M. (2022). Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology, 15(1), 83. https://doi.org/10.1186/s13045-022-01296-0

  • Bolhassani, A., Javanzad, S., Saleh, T., Hashemi, M., Aghasadeghi, M. R., … & Sadat, S. M. (2014). Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Human Vaccines & Immunotherapeutics, 10(2), 321–332. https://doi.org/10.4161/hv.26796

  • Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., … & Hashemi, M. (2022). AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomedicine & Pharmacotherapy, 146, 112563. https://doi.org/10.1016/j.biopha.2021.112563

  • Hashemi, M., Moosavi, M. S., Abed, H. M., Dehghani, M., Aalipour, M., Heydari, E. A., … & Mirzaei, S. (2022). Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacological Research, 184, 106418. https://doi.org/10.1016/j.phrs.2022.106418

  • Sadrkhanloo, M., Entezari, M., Orouei, S., Ghollasi, M., Rezaei, S., Hejazi, E. S., … & Hashemi, M. (2022). STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. Pharmacological Research, 182, 106311. https://doi.org/10.1016/j.phrs.2022.106311

Ajay Kumar Rana | Biology and Life Sciences | Outstanding Contribution to Forensic Biology Award

Dr. Ajay Kumar Rana | Biology and Life Sciences | Outstanding Contribution to Forensic Biology Award

Central Forensic Science Laboratory | India

Dr. Ajay Kumar Rana is a highly accomplished forensic biologist and Scientist-B at the Central Forensic Science Laboratory, Hyderabad, under the Ministry of Home Affairs, India, with over a decade of expertise in DNA analysis, serology, and forensic molecular biology. He earned his Ph.D. from Jawaharlal Nehru University, New Delhi/Central Drug Research Institute, where he conducted pioneering work on methyltransferases of Wolbachia endosymbionts and anti-filarial drug development, followed by postdoctoral training at the Israel Institute of Technology (Technion-IIT) focusing on tRNA methyltransferases and ribonucleases. Dr. Ajay Kumar Rana’s professional journey spans roles from Scientific Assistant to Assistant Director (Biology) at the State Forensic Science Laboratory, Jharkhand, and now leadership of the DNA/Biology Division at CFSL Hyderabad, where he manages NABL-accredited laboratories, oversees quality compliance, and supervises forensic sample analysis. He has reported over 750 cases, attended more than 35 crime scenes, and mentored numerous scientific assistants and law enforcement personnel in forensic protocols. His research integrates molecular biology, DNA methylation, and advanced forensic genetics, including strategies for extracting DNA from challenging samples, contributing to both theoretical knowledge and practical forensic applications. Dr. Ajay Kumar Rana has published 12 peer-reviewed articles and book chapters, accumulating 208 citations with an h-index of 8, as indexed in Scopus, in journals including Antimicrobial Agents and Chemotherapy (2013), Frontiers in Genetics (2016), and Egyptian Journal of Forensic Sciences (2018). Recognized with prestigious awards including the DST-SERB International Travel Award, CSIR fellowships, and national competitive selections, Dr. Rana exemplifies scientific excellence, innovation, and dedication to advancing forensic biology.

Profile: Scopus | Google Scholar | ORCID | LinkedIn

Featured Publications

Rana, A. K., & Misra-Bhattacharya, S. (2013). Current drug targets for helminthic diseases. Parasitology Research, 112(5), 1819–1831.

Rana, A. K., & Ankri, S. (2016). Reviving the RNA world: An insight into the appearance of RNA methyltransferases. Frontiers in Genetics, 7, 99.

Rana, A. K., & Kumar, N. (2023). Current wildlife crime (Indian scenario): Major challenges and prevention approaches. Biodiversity and Conservation, 32(5), 1473–1491.

Rana, A. K. (2018). Crime investigation through DNA methylation analysis: Methods and applications in forensics. Egyptian Journal of Forensic Sciences, 8(7), 38.

Kushwaha, S., Singh, P. K., Rana, A. K., & Misra-Bhattacharya, S. (2011). Cloning, expression, purification and kinetics of trehalose-6-phosphate phosphatase of filarial parasite Brugia malayi. Acta Tropica, 119(2–3), 151–159.

Kumar, N., Yadav, V. K., & Rana, A. K. (2017). Wildlife forensic: Current techniques and their limitations. Journal of Forensic Science & Criminology, 5(4), 402.

Singh, P. K., Kushwaha, S., Rana, A. K., & Misra-Bhattacharya, S. (2014). Cofactor independent phosphoglycerate mutase of Brugia malayi induces a mixed Th1/Th2 type immune response and inhibits larval development in the host. BioMed Research International, 2014, 590281.

Kushwaha, S., Singh, P. K., Rana, A. K., & Misra-Bhattacharya, S. (2013). Immunization of Mastomys coucha with Brugia malayi recombinant trehalose-6-phosphate phosphatase results in significant protection against homologous challenge infection. PLoS ONE, 8(8), e72585.

Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Prof. Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Wannan Medical College | China

Prof. Zhiliang Xu, affiliated with Wannan Medical College, Wuhu, China, is a distinguished molecular biologist and epigenetics researcher whose work focuses on histone ubiquitination, chromatin remodeling, and their implications in neurological disorders, cancer, gametogenesis, and cellular reprogramming. He earned his Ph.D. from the State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences in 2017. According to Scopus, Prof. Zhiliang Xu has authored 11 publications, which have been cited 34 times, and he holds an h-index of 4, demonstrating the impact of his research in the scientific community. His seminal studies elucidated the role of H2B ubiquitination in chromatin relaxation during meiosis and cellular reprogramming, published in journals such as Nucleic Acids Research (2016), Cell Proliferation (2021), and Reproduction (2017). His recent work on neuronal repair, gut-liver axis regulation in diabetes, and genomic approaches to thalassemia has been featured in FASEB Journal (2025), Annals of Hematology (2025), and Neuroscience Letters (2025). Prof. Zhiliang Xu leads multiple high-impact national and provincial research projects, serves as a peer reviewer for journals including Scientific Reports and Neurochemical Research, and evaluates theses for graduate and doctoral candidates. Recognized with the 2021 National Maternal and Child Health Science and Technology Award (First Prize), the 2022 Guangzhou High-level Talent Award, and the 2024 Outstanding Young Talent honor in Anhui Province, Prof. Zhiliang Xu continues to advance fundamental understanding of chromatin biology and epigenetic regulation, exemplifying excellence, mentorship, and translational scientific impact, making him an outstanding candidate for the Best Researcher Award.

Profile: Scopus | ORCID

Featured Publications

1. Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025). Beyond transfusions and transplants: Genomic innovations rewriting the narrative of thalassemia. Annals of Hematology.

2. Zhang, Y., Wang, J., Huang, S., Liu, M., Zhao, Y., Xu, Z., & Zhu, X. (2025). Electroacupuncture preconditioning alleviates cortical neuronal injury in cerebral ischemia-reperfusion by rebalancing HES1 and NF-κB expression. Neuroreport.

3. Yan, X., Shi, L., Zhu, X., Zhao, J., Zhao, Y., Luo, J., Li, Q., & Xu, Z. (2025). From microbial homeostasis to systemic pathogenesis: A narrative review on gut flora’s role in neuropsychiatric, metabolic, and cancer disorders. Journal of Inflammation Research.

4. Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025). Neurodegenerative diseases and neuroinflammation-induced apoptosis. Open Life Sciences.

5. Li, Q., Zhang, L., Sun, Y., Du, Z., Xu, S., Wang, X., Wei, S., Tao, Y., Li, B., Jiang, J., Di, G., Huang, Y., & Xu, Z. (2025). p53 modulates the gut-liver axis via PI3K/AKT/Wnt signaling pathways in type 2 diabetes. FASEB Journal.

6. Li, Q., Yan, X., Zhao, Y., Xu, Z., & Zhu, X. (2025). Paeonol mitigates chronic stress-induced amygdalar neuronal damage through glycogen synthase kinase-3β/calcineurin axis regulation of synaptic plasticity. Neuroreport.

7. Zhu, X., Zhang, Y., Yan, X., Zhao, Y., Shi, L., Sun, Z., Meng, K., Zong, Y., Li, Q., & Xu, Z. (2025). Paeonol facilitates the repair of neuronal damage in the mPFC caused by chronic stress via the Rho GTPases-cofilin1 signaling pathway. Neuroscience Letters, 138329.

Meng Ning | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Dr. Meng Ning | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Chiba University | China

Dr. Meng Ning is an accomplished researcher at Chiba University, Japan, recognized for her pioneering work in the epigenetic regulation of cancer. She has made substantial contributions to understanding the non-catalytic roles of chromatin regulators, particularly in gastric cancer. Her expertise bridges molecular biology and clinical gastrointestinal oncology, enabling her to translate laboratory discoveries into potential therapeutic strategies. Meng Ning is known for her meticulous experimental design, innovative application of genome-editing technologies, and dedication to advancing cancer research through both independent studies and collaborative projects.

Professional Profile

ORCID

Education

Dr. Meng Ning completed her doctoral studies at Chiba University, Japan, where she focused on elucidating novel mechanisms of cancer progression. Her Ph.D. research revealed a previously unrecognized non-catalytic function of SETD1A in gastric cancer via the E2F4–TAF6 axis. Employing advanced techniques including transcriptomics, epigenomics, and genome-editing approaches, she was able to demonstrate this mechanism independently of traditional methyltransferase activity. Her academic training combines rigorous laboratory research with a strong foundation in clinical oncology, preparing her to conduct translational studies that link fundamental discoveries with therapeutic potential.

Experience

Dr. Meng Ning has extensive experience in both experimental and translational cancer research. She has collaborated with the Department of Pathology at the University of Tokyo to analyze clinical gastric cancer specimens, integrating molecular findings with patient data. Her work spans NGS-based studies, CRISPR genome editing, and multi-omics analyses, reflecting a versatile approach to cancer biology. Beyond laboratory research, she has contributed to the mentorship of junior researchers, participated in collaborative projects across institutions, and actively engaged in the scientific community through professional society memberships and research networks.

Research Interests

Dr. Meng Ning’s primary research interest lies in the epigenetic regulation of cancer, with a focus on non-catalytic functions of chromatin regulators. She investigates how these regulators influence tumor proliferation, cellular signaling, and transcriptional networks using advanced molecular biology techniques. Her research integrates next-generation sequencing, genome editing, and integrative bioinformatics to identify novel mechanisms underlying cancer progression. By connecting these molecular insights with clinical oncology, she aims to identify potential therapeutic targets and contribute to the development of innovative cancer treatments.

Awards

Dr. Meng Ning is nominated for the Best Researcher Award in recognition of her outstanding contributions to cancer epigenetics and translational oncology. Her research has introduced novel concepts in understanding chromatin regulator function and tumor biology, demonstrating originality, technical excellence, and significant impact in the field. Her dedication to advancing cancer research through rigorous experimentation and collaborative endeavors positions her as a leading researcher in her discipline.

Publications

Dr. Meng Ning has authored several high-impact, SCI-indexed publications as first or contributing author. Her work demonstrates innovative methodologies and deep insights into the molecular mechanisms of cancer:

Title: Non-catalytic role of SETD1A promotes gastric cancer cell proliferation through the E2F4–TAF6 axis in the cell cycle
Journal: Cell Death & Disease
Published on: 2025-08-23

Title: Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K
Journal: Breast Cancer Research
Published on: 2025-08-11

Title: Integrated enhancer regulatory network by enhancer–promoter looping in gastric cancer
Journal: NAR Cancer
Published on: 2024-04-08

Conclusion

Dr. Meng Ning exemplifies excellence in scientific research through her innovative studies in cancer epigenetics and her commitment to translational application. Her work bridges basic molecular discoveries and clinical oncology, offering new avenues for therapeutic development. With a combination of technical skill, collaborative engagement, and visionary research, Meng Ning stands out as a highly deserving candidate for the Best Researcher Award. Her contributions not only advance the understanding of cancer biology but also inspire ongoing innovation in epigenetic and translational research.

Jie Huang | Biological Sciences | Best Researcher Award

Dr. Jie Huang | Biological Sciences | Best Researcher Award

University of Oxford | United Kingdom

Dr. Jie Huang (黄杰), is a distinguished plant biologist currently serving as a postdoctoral researcher at the Department of Biology, University of Oxford. His research focuses on molecular plant–pathogen interactions, alternative splicing, and effector biology. Dr. Huang has made substantial contributions to our understanding of how pathogens manipulate plant immune responses and has published widely in high-impact journals.

Professional profile👤

Google Scholar

Strengths for the Awards✨

1. Strong Academic Background & Training

  • PhD from Nanjing Agricultural University under a leading expert, Prof. Suomeng Dong.

  • Postdoctoral experience at the prestigious University of Oxford, a global hub for biological sciences.

2. Consistent and High-Impact Research Output

  • Multiple first-author and corresponding-author publications in top-tier journals such as Nature Communications, Advanced Science, The Plant Cell, Molecular Plant, and New Phytologist.

  • His research appears in elite plant biology and molecular journals, indicating significant peer recognition and impact.

3. Innovation in Research

  • Pioneered discoveries related to alternative splicing in plant immunity, plant-pathogen interactions, and protein-peptide interactions, a critical frontier in molecular plant pathology.

  • Integration of computational tools (AlphaFold-Multimer) in cross-kingdom interaction studies, reflecting interdisciplinary sophistication.

4. Competitive Funding Record

  • Secured prestigious funding from national (NSFC), provincial, and postdoctoral foundations in China as Principal Investigator, demonstrating independent scientific leadership.

5. International Collaboration & Mobility

  • Experience at institutions in China, the UK, and the USA, showcasing global integration and collaborative capacity.

  • Short-term training and collaborative publications with international partners, enhancing his scientific network and adaptability.

🎓 Education

 Dr. Huang began his academic journey with a Bachelor’s degree in Plant Science from Anhui Agricultural University (2009–2013). He then pursued his Ph.D. in Plant Pathology at Nanjing Agricultural University (2013–2018), where he was mentored by the esteemed Prof. Suomeng Dong. His doctoral research laid a strong foundation for his expertise in host–pathogen molecular dynamics.

🧪 Experience

 Following his Ph.D., Dr. Huang worked as a postdoctoral researcher at Nanjing Agricultural University (2018–2021), continuing under Prof. Dong’s supervision. In 2019, he broadened his global research exposure as a visiting scholar at Colorado State University with Prof. Anireddy Reddy. Since January 2022, he has been advancing his research at the University of Oxford under Prof. Renier A. L. van der Hoorn, contributing to frontier studies in plant proteomics and immunity.

🔬 Research Interests On Biological Sciences

🌿 Dr. Huang’s research delves into:

  • Alternative splicing in plant immunity

  • Effector biology in oomycete pathogens

  • Protease-targeting mechanisms at the plant–pathogen interface

  • Use of AlphaFold and other computational tools to predict protein interactions
    His work bridges molecular biology, bioinformatics, and biotechnology for improving crop resistance strategies.

🏆 Awards and Funding

 As a Principal Investigator, Dr. Huang has secured several prestigious research grants, including:

  • National Natural Science Foundation of China (No. 31901862)

  • Natural Science Foundation of Jiangsu Province (SBK2019040604)

  • Fundamental Research Funds for Central Universities (KYQN202009)

  • China Postdoctoral Science Foundation (2018M640494)

  • Special Postdoctoral Science Fund (2020T130306)

These awards reflect his scientific rigor and innovative research in plant molecular biology.

📚 Publications

1. A Phytophthora effector manipulates host histone acetylation and reprograms defense gene expression to promote infection
Authors: L Kong, X Qiu, J Kang, Y Wang, H Chen, J Huang, M Qiu, Y Zhao, G Kong, …
Year: 2017
Cited by: 144

2. An oomycete plant pathogen reprograms host pre-mRNA splicing to subvert immunity
Authors: J Huang, L Gu, Y Zhang, T Yan, G Kong, L Kong, B Guo, M Qiu, Y Wang, …
Year: 2017
Cited by: 120

3. Phytophthora effectors modulate genome-wide alternative splicing of host mRNAs to reprogram plant immunity
Authors: J Huang, X Lu, H Wu, Y Xie, Q Peng, L Gu, J Wu, Y Wang, ASN Reddy, …
Year: 2020
Cited by: 84

4. The Activation of Phytophthora Effector Avr3b by Plant Cyclophilin is Required for the Nudix Hydrolase Activity of Avr3b
Authors: G Kong, Y Zhao, M Jing, J Huang, J Yang, Y Xia, L Kong, W Ye, Q Xiong, …
Year: 2015
Cited by: 84

5. The Phytophthora sojae RXLR effector Avh238 destabilizes soybean Type2 GmACSs to suppress ethylene biosynthesis and promote infection
Authors: B Yang, Y Wang, B Guo, M Jing, H Zhou, Y Li, H Wang, J Huang, Y Wang, …
Year: 2019
Cited by: 71

6. AlphaFold-Multimer predicts cross-kingdom interactions at the plant-pathogen interface
Authors: F Homma, J Huang, RAL van der Hoorn
Year: 2023
Cited by: 69

7. Pathogen manipulation of chloroplast function triggers a light-dependent immune recognition
Authors: C Gao, H Xu, J Huang, B Sun, F Zhang, Z Savage, C Duggan, T Yan, …
Year: 2020
Cited by: 65

8. Cleavage of a pathogen apoplastic protein by plant subtilases activates host immunity
Authors: S Wang, R Xing, Y Wang, H Shu, S Fu, J Huang, JK Paulus, M Schuster, …
Year: 2021
Cited by: 40

9. Natural allelic variations provide insights into host adaptation of Phytophthora avirulence effector PsAvr3c
Authors: J Huang, L Chen, X Lu, Q Peng, Y Zhang, J Yang, BY Zhang, B Yang, …
Year: 2019
Cited by: 32

10. Phytophthora sojae apoplastic effector AEP1 mediates sugar uptake by mutarotation of extracellular aldose and is recognized as a MAMP
Authors: Y Xu, Y Zhang, J Zhu, Y Sun, B Guo, F Liu, J Huang, H Wang, S Dong, …
Year: 2021
Cited by: 31

📝 Conclusion

🌟 Dr. Jie Huang is a rising star in plant molecular biology, combining classical genetics, proteomics, and cutting-edge computational tools to unravel the complexities of plant immunity and pathogen virulence. His international collaborations, funding success, and impactful publications position him as a strong nominee for any prestigious research award recognizing scientific excellence in plant sciences.

Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Dr. Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Epidemiologist | Pfizer UK Ltd | United Kingdom

Dr. Andrew Vyse is a seasoned epidemiologist with extensive experience in both the pharmaceutical industry and public health research. He specializes in vaccine-preventable and potentially vaccine-preventable infections, contributing significantly to the field with over 80 peer-reviewed publications.

Profile

Scopus

Strengths for the Awards

  • Prolific Research Contributions:
    • Dr. Vyse has authored over 80 peer-reviewed publications, which demonstrates a consistent and significant contribution to epidemiological research, particularly in the area of vaccine-preventable diseases.
    • Recent publications cover diverse, critical topics such as Lyme disease, pneumococcal vaccination, RSV, and cost-effectiveness of vaccine strategies. This breadth indicates a comprehensive understanding of the field.
  • Impact on Public Health:
    • His work in vaccine-preventable diseases directly contributes to public health improvements, including informing vaccination strategies and addressing vaccine-preventable hospitalizations.
  • Industry and Academic Experience:
    • A balance of pharmaceutical industry experience (Pfizer and GSK) and public health research (UKHSA) highlights his ability to bridge scientific research with practical applications.
    • This unique positioning allows him to contribute to both policy-making and the development of new vaccine technologies.

Education 🎓

Dr. Vyse holds a PhD and MSc, reflecting his robust academic foundation in epidemiology and public health. His educational background has equipped him with the expertise to drive impactful research and clinical applications in his field.

Professional Experience 💼

  • Feb 2017 – Present: Clinical Epidemiologist at Pfizer UK Ltd, supporting the UK Medical Team and global Scientific Affairs for vaccines including pneumococcal, RSV, COVID, meningococcal, and a candidate Lyme vaccine.
  • Jan 2009 – Jan 2017: Global Epidemiologist at GSK Vaccines, contributing to portfolios for meningococcal, DTP, and rotavirus vaccines.
  • May 1993 – Dec 2008: Clinical Scientist at the UK Health Security Agency (formerly Public Health England), focusing on surveillance and epidemiological research for vaccine-preventable infections.

Research Interests On Medicine 🧬

Dr. Vyse’s research interests revolve around vaccine-preventable diseases, with a particular focus on respiratory infections, Lyme borreliosis, and strategies to optimize vaccination coverage in vulnerable populations.

Awards and Recognition 🏆

Dr. Vyse has been recognized for his contributions to epidemiology and vaccine research. His work has garnered significant academic and industry accolades, reflecting his impact on public health initiatives and vaccine development.

Publications 🔖

1. Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus

  • Authors: Vyse, A., Wright, H., Begier, E.
  • Year: 2024
  • Citations: 0

2. Using Catalytic Models to Interpret Age-Stratified Lyme Borreliosis Seroprevalence Data

  • Authors: Vyse, A., Colby, E.
  • Year: 2024
  • Citations: 0

3. Incidence of symptomatic Lyme borreliosis in nine European countries

  • Authors: Angulo, F.J., Colby, E., Lebech, A.-M., Moïsi, J.C., Stark, J.H.
  • Year: 2024
  • Citations: 1

4. Adult risk groups for vaccine-preventable respiratory infections: an overview of the UK environment

  • Authors: Reynard, C., Campling, J., Gordon, A.L., Wright, H., Ellsbury, G.
  • Year: 2024
  • Citations: 0

5. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

  • Authors: Wilson, M., Lucas, A., Mendes, D., Ellsbury, G.F., Perdrizet, J.
  • Year: 2023
  • Citations: 9

6. Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK

  • Authors: Schley, K., Kowalik, J.C., Sullivan, S.M., Tichy, E., Findlow, J.
  • Year: 2023
  • Citations: 0

7. Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?

  • Authors: Neri, M., Brassel, S., Schirrmacher, H., Steuten, L., Hamson, E.
  • Year: 2023
  • Citations: 4

8. A Retrospective Database Study of Lyme Borreliosis Incidence in Poland from 2015 to 2019

  • Authors: Paradowska-Stankiewicz, I., Zbrzezniak, J., Skufca, J., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 5

9. Incidence of Lyme Borreliosis in Germany

  • Authors: Skufca, J., Tran, T.M.P., Brestrich, G., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 2

10. Incidence of Lyme Borreliosis in the Dutch General Practice Population

  • Authors: Houben, E., De Jong, H., Penning-Van Beest, F., Herings, R., Stark, J.H.
  • Year: 2023
  • Citations: 3

Conclusion 🌐

Dr. Andrew Vyse’s work bridges the pharmaceutical industry and public health research, driving innovations in vaccine development and disease prevention. His dedication to epidemiology continues to advance global health outcomes, underpinned by his extensive research, impactful publications, and commitment to public health initiatives.